Amy Stark to Cell Line
This is a "connection" page, showing publications Amy Stark has written about Cell Line.
Connection Strength
0.330
-
Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes? Pharmacogenomics. 2013 Apr; 14(5):447-50.
Score: 0.078
-
Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010 Dec 10; 87(6):829-33.
Score: 0.066
-
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
Score: 0.063
-
Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci. 2017 Mar 18; 18(3).
Score: 0.026
-
Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208.
Score: 0.021
-
EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220.
Score: 0.021
-
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20.
Score: 0.020
-
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
Score: 0.017
-
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
Score: 0.017